Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 11/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14188605 | 0.95 | CDC7 (0.43) | CDC7FPR2KDM4EXBP1S1PR1 | |
| SCHEMBL5002321 | 0.95 | CDC7 (0.47) | CDC7S1PR1S1PR3ALDH1A1HPGD | |
| SCHEMBL4994432 | 0.94 | CDC7 (0.43) | CDC7FPR2KDM4ES1PR1S1PR3 | |
| SCHEMBL5000213 | 0.94 | CDC7 (0.44) | CDC7FPR2MEN1KMT2AHPGD | |
| SCHEMBL4995825 | 0.92 | CDC7 (0.46) | CDC7FPR2KDM4ES1PR1S1PR3 | |
| SCHEMBL4997519 | 0.91 | CDC7 (0.45) | CDC7FPR2KDM4ES1PR1S1PR3 | |
| SCHEMBL4994509 | 0.89 | CDC7 (0.43) | CDC7FPR2KDM4EMEN1KMT2A | |
| SCHEMBL5002596 | 0.88 | SHMT2 (0.46) | CDC7S1PR1S1PR3ALDH1A1HPGD | |
| SCHEMBL14188684 | 0.88 | CDC7 (0.46) | CDC7S1PR1S1PR3ALDH1A1MEN1 | |
| SCHEMBL5002697 | 0.88 | HSD17B10 (0.41) | CDC7KDM4ES1PR1S1PR3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | HANAU CATHLEEN E | 2008-05-15 | — | — | US | disclosed |
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | HANAU CATHLEEN E | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | MKNK2, MAPKAPK2, MAP3K2 | CDC7 487/4885FPR2 755/4885KDM4E 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.